Journal
CANCER INVESTIGATION
Volume 28, Issue 9, Pages 932-943Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/07357907.2010.496757
Keywords
Inflammation; Endothelin-1; ETAR; ETBR; Bone; Metastasis; Immunocompetent; Migration; Cytokine; Chemokines
Categories
Funding
- Susan G. Komen Foundation
- UNC Charlotte
- Susan G. Komen Breast Cancer Foundation (BTR) [0503702]
Ask authors/readers for more resources
We investigated the effects of the endothelin-1 (ET-1) receptor dual antagonist (Bosentan (R)) on the inflammatory cytokines and the chemoattractant molecules associated with breast cancer growth and the development of tumor infiltration in bone explants. Immunocompetent mice implanted with the murine mammary carcinoma 4T1 cells in a skin-fold chamber and treated with Bosentan (R) had reduced tumor growth (p < .05). ET-1 promoted the secretion of the anti-inflammatory soluble tumor necrosis factor (TNF) receptor and IL12 p40 in vitro. The Bosentan (R) treatment in vivo was associated with a local increase of the anti-inflammatory IL-1 alpha cytokine concentration and decrease of the pro-inflammatory TNF-alpha and IL-17 cytokine concentrations (p < .05).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available